Recent Posts in ‘Regenerative Medicine Headline’
Top Three Regenerative Medicine Companies Targeting Ischemic Conditions
As we discussed in our first article on elite regenerative medicine companies, there are several methodologies to delineating the “cream of the crop.” In this exercise, we will take a look at the impact that regenerative medicine technologies can have on ischemic conditions – where tissue in the heart, brain, organs or limbs are damaged
Five Regenerative Medicine Companies Worthy of Portfolio Addition
Broadly speaking, regenerative medicine is an innovative new area of medicine that is focused on the development of new therapies that enable healing and repair of the body in ways that overcome the limitations of conventional medical treatments. Regenerative medicine uses a range of approaches, including cell based therapies, stem cells, tissue engineering and others,
Athersys Reaffirms Position as Regenerative Medicine Leader with Cell Therapy Manufacturing Award for MultiStem® and Recent Research Progress in Treating Neurological Conditions
On the heels of a steady stream of corporate developments in October that showcased the promising data that continues to build regarding its MultiStem® cell therapy, Athersys, Inc. (NASDAQ: ATHX) announced Thursday morning that its subsidiary, ReGenesys BVBA, recently received the BioProcess International Award for the “Technical Application of the Decade” in Manufacturing for its
Cardium’s (CXM) Catheter-based Method Boosts Gene Delivery to Heart
Cardium Therapeutics Ltd. (NYSE MKT: CXM), a health sciences and regenerative medicine company focused on the acquisition of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR),
FDA Approval for Arena Anti-Obesity Drug Puts Spotlight on Vivus, Athersys and More
Weight loss drugs are back in the news with Arena Pharmaceuticals (NASDAQ: ARNA) finally winning Food and Drug Administration approval on Wednesday for lorcaserin, which will be sold under the name Belviq by Eisai Co. Ltd. (Pink Sheets: ESALY), a division of Arena. The FDA has been very hesitant to approve any new weight loss
May Proves to be Another Solid Month for Regenerative Medicine Industry
Each month brings more advancements in the field of regenerative medicine with May recording a major milestone as Osiris Therapeutics Inc. (NASDAQ: OSIR) announced market authorization from Health Canada to market its stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children. The landmark clearance marked the world’s first regulatory
Athersys (ATHX) Reports Solid Progress in 2011
Athersys Inc. (Nasdaq: ATHX), a clinical stage biotechnology company focused on the development of its proprietary MultiStem® cell therapy product for the treatment of numerous diseases and conditions, similar to companies like Mesoblast (MSB: ASX) and ThermoGenesis Corp (Nasdaq: KOOL), recently reported solid progress during the fourth quarter and full year. Click Here: View the